Skip to content
Inciteful Med

The Biology and Genetic Types of AGS

Last updated:

Aicardi-Goutières syndrome (AGS) is caused by genetic mutations that prevent cells from clearing out leftover DNA and RNA. The immune system mistakes this buildup for a virus, triggering chronic inflammation. The specific gene involved helps doctors predict symptoms and guide care for your child.

Key Takeaways

  • • AGS is caused by a genetic glitch where the immune system attacks the body's own leftover DNA and RNA.
  • • This immune response triggers the release of Type I Interferon, causing chronic inflammation in the brain and body.
  • • There are several genetic subtypes of AGS, such as TREX1 and RNASEH2B, which influence a child's symptoms and disease progression.
  • • The condition is most commonly inherited in an autosomal recessive pattern, meaning both parents carry the gene mutation.
  • • Knowing your child's specific AGS genotype helps doctors create a targeted monitoring plan for their long-term health.

Understanding the biology of Aicardi-Goutières syndrome (AGS) begins with a “glitch” in how the body handles its own genetic material [1]. While we usually think of DNA and RNA as the building blocks of life, your child’s immune system sees these “self-nucleic acids” as a threat, triggering a constant state of internal “viral alarm” [2][3].

The “Self-Nucleic Acid” Glitch

In a typical cell, there is a constant process of creating and cleaning up tiny pieces of DNA and RNA. AGS is caused by a mutation in one of several genes that act like “cellular janitors” [1][4].

  • The Job: Normally, these genes produce proteins that break down leftover pieces of DNA or RNA so the immune system never sees them [5][6].
  • The Glitch: When these genes are mutated, the “trash” (self-nucleic acids) piles up inside the cell [7][6].
  • The Alarm: A sensor in the cell (like cGAS or MDA5) finds this trash and mistakes it for a viral infection [5][8]. This triggers the release of Type I Interferon, a powerful chemical that causes the brain and body to stay in a state of high-alert inflammation [1][2].

Genetic Subtypes and What They Mean

The specific gene affected in your child (their genotype) often influences how the disease looks and progresses (their phenotype) [9][10]. While the most common genes are listed below, a small percentage of children may have a clinical diagnosis of AGS without an identified mutation [11][12].

Affected Gene Subtype Common Associated Features
TREX1 AGS1 Often severe; early onset in the first weeks of life [10][9].
RNASEH2B AGS2 Most common type; can be milder or progress more slowly; some children have preserved intellect [13][14].
SAMHD1 AGS5 Higher risk for moyamoya (narrowing of brain blood vessels) and skin/joint issues [15][16].
ADAR1 AGS6 Can cause skin pigment changes or sudden movement issues (striatal necrosis) later in childhood [17][18].
IFIH1 AGS7 A “gain-of-function” mutation where the sensor itself is overactive; often involves severe skin, gut, or lung issues [19][20].

How It Is Inherited

AGS can be passed down in two main ways. Your genetic test results will specify which one applies to your family [21].

  • Autosomal Recessive: This is the most common path [16]. Both parents are “carriers” of one mutated copy of the gene but have no symptoms themselves. For each pregnancy, there is a 25% (1 in 4) chance the child will inherit both mutated copies and have AGS [21].
  • Autosomal Dominant: In this case, only one mutated copy of the gene is needed to cause the condition [21]. This can be inherited from one parent who also has the mutation, or it can be a “de novo” mutation, meaning it happened for the first time in the child and neither parent is a carrier [18][21].

Knowing the specific gene involved is the “roadmap” your doctors will use to monitor your child’s health, from checking their blood vessels to testing their thyroid or kidney function [22][23].

Frequently Asked Questions

What causes Aicardi-Goutières syndrome?
AGS is caused by a genetic mutation that affects how cells clean up leftover DNA and RNA. Because this genetic material builds up, the immune system mistakes it for a viral infection and triggers constant, damaging inflammation.
Does the specific AGS gene mutation my child has matter?
Yes, the specific gene affected, known as the genotype, often influences how the disease progresses. Different gene mutations, such as TREX1 or SAMHD1, can indicate a higher risk for specific complications like blood vessel narrowing or skin issues.
What is Type I Interferon's role in AGS?
Type I Interferon is a powerful chemical released by the immune system when it senses a viral infection. In AGS, the immune system's false alarm causes a constant release of this chemical, keeping the brain and body in a state of high-alert inflammation.
How is AGS inherited?
AGS is usually inherited in an autosomal recessive pattern, meaning both parents are healthy carriers of the mutated gene. Less commonly, it can be autosomal dominant, where only one mutated copy is needed to cause the condition, which may be inherited or happen spontaneously.

Questions for Your Doctor

  • • Which specific AGS gene was identified in our child, and what is its normal role in the body?
  • • Is our child's genetic mutation inherited in an autosomal recessive or autosomal dominant manner?
  • • Based on this genotype (e.g., SAMHD1 or IFIH1), are there specific organs like the kidneys, heart, or blood vessels we should monitor more closely?
  • • How does our child's specific mutation typically affect long-term developmental milestones compared to other types?

Questions for You

  • • Do you have a family history of neurological conditions, autoimmune diseases, or unexplained infant loss?
  • • Have you met with a genetic counselor to discuss what these results mean for your family and future children?
  • • What are your primary concerns regarding the specific risks associated with your child's subtype (e.g., blood vessel health or skin issues)?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Aicardi-Goutières syndrome: A monogenic type I interferonopathy.

    Liu A, Ying S

    Scandinavian journal of immunology 2023; (98(4)):e13314 doi:10.1111/sji.13314.

    PMID: 37515439
  2. 2

    Generation of three induced pluripotent cell lines (iPSCs) from an Aicardi-Goutières syndrome (AGS) patient harboring a deletion in the genomic locus of the sterile alpha motif and HD domain containing protein 1 (SAMHD1).

    Fuchs NV, Schieck M, Neuenkirch M, et al.

    Stem cell research 2020; (43()):101697 doi:10.1016/j.scr.2019.101697.

    PMID: 32062129
  3. 3

    Aicardi-Goutières syndrome (AGS): recurrent fetal cardiomyopathy and pseudo-TORCH syndrome.

    Panigrahy N, Bakhru S, Lingappa L, Chirla D

    BMJ case reports 2022; (15(12)) doi:10.1136/bcr-2022-249192.

    PMID: 36581356
  4. 4

    The DNase TREX1 is a substrate of the intramembrane protease SPP with implications for disease pathogenesis.

    Tever OK, Mentrup T, Chinn IK, et al.

    Cellular and molecular life sciences : CMLS 2025; (82(1)):107 doi:10.1007/s00018-025-05645-5.

    PMID: 40072623
  5. 5

    Mutations in the non-catalytic polyproline motif destabilize TREX1 and amplify cGAS-STING signaling.

    Shim A, Luan X, Zhou W, et al.

    bioRxiv : the preprint server for biology 2024; doi:10.1101/2024.01.04.574136.

    PMID: 38260344
  6. 6

    A central role for PI3K-AKT signaling pathway in linking SAMHD1-deficiency to the type I interferon signature.

    Oh C, Ryoo J, Park K, et al.

    Scientific reports 2018; (8(1)):84 doi:10.1038/s41598-017-18308-8.

    PMID: 29311560
  7. 7

    Mutations in the non-catalytic polyproline motif destabilize TREX1 and amplify cGAS-STING signaling.

    Shim A, Luan X, Zhou W, et al.

    Human molecular genetics 2024; (33(18)):1555-1566 doi:10.1093/hmg/ddae089.

    PMID: 38796715
  8. 8

    ADAR1 interaction with Z-RNA promotes editing of endogenous double-stranded RNA and prevents MDA5-dependent immune activation.

    de Reuver R, Dierick E, Wiernicki B, et al.

    Cell reports 2021; (36(6)):109500 doi:10.1016/j.celrep.2021.109500.

    PMID: 34380029
  9. 9

    Developmental Outcomes of Aicardi Goutières Syndrome.

    Adang L, Gavazzi F, De Simone M, et al.

    Journal of child neurology 2020; (35(1)):7-16 doi:10.1177/0883073819870944.

    PMID: 31559893
  10. 10

    Exploration of Gross Motor Function in Aicardi-Goutières Syndrome.

    Gavazzi F, Glanzman AM, Woidill S, et al.

    Journal of child neurology 2023; (38(8-9)):518-527 doi:10.1177/08830738231188753.

    PMID: 37499181
  11. 11

    Phenotypic and Molecular Spectrum of Aicardi-Goutières Syndrome: A Study of 24 Patients.

    Al Mutairi F, Alfadhel M, Nashabat M, et al.

    Pediatric neurology 2018; (78()):35-40 doi:10.1016/j.pediatrneurol.2017.09.002.

    PMID: 29239743
  12. 12

    Nucleotide metabolism, leukodystrophies, and CNS pathology.

    Gavazzi F, Gonzalez CD, Arnold K, et al.

    Journal of inherited metabolic disease 2024; (47(5)):860-875 doi:10.1002/jimd.12721.

    PMID: 38421058
  13. 13

    Late diagnosis and atypical brain imaging of Aicardi-Goutières syndrome: are we failing to diagnose Aicardi-Goutières syndrome-2?

    Svingen L, Goheen M, Godfrey R, et al.

    Developmental medicine and child neurology 2017; (59(12)):1307-1311 doi:10.1111/dmcn.13509.

    PMID: 28762473
  14. 14

    Diagnosis of Aicardi-Goutières Syndrome in Adults: A Case Series.

    Videira G, Malaquias MJ, Laranjinha I, et al.

    Movement disorders clinical practice 2020; (7(3)):303-307 doi:10.1002/mdc3.12903.

    PMID: 32258229
  15. 15

    Intracerebral large artery disease in Aicardi-Goutières syndrome with TREX1 mutation: a case report.

    Wu CC, Peng SS, Lee WT

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2020; (41(11)):3353-3356 doi:10.1007/s10072-020-04516-0.

    PMID: 32524323
  16. 16

    SAMHD1 compound heterozygous rare variants associated with moyamoya and mitral valve disease in the absence of other features of Aicardi-Goutières syndrome.

    Karla AR, Pinard A, Boerio ML, et al.

    American journal of medical genetics. Part A 2024; (194(4)):e63486 doi:10.1002/ajmg.a.63486.

    PMID: 38041217
  17. 17

    Case Report: Aicardi-Goutières Syndrome Type 6 and Dyschromatosis Symmetrica Hereditaria With Congenital Heart Disease and Mitral Valve Calcification - Phenotypic Variants Caused by Adenosine Deaminase Acting on the RNA 1 Gene Homozygous Mutations.

    Liu L, Zhang L, Huang P, et al.

    Frontiers in pediatrics 2022; (10()):852903 doi:10.3389/fped.2022.852903.

    PMID: 35832578
  18. 18

    Dyschromatosis symmetrica hereditaria: A clue to early diagnosis of Aicardi-Goutières syndrome.

    Ahmed F, Do N, Vanderver AL, Treat JR

    Pediatric dermatology 2024; (41(1)):156-157 doi:10.1111/pde.15437.

    PMID: 37770123
  19. 19

    Unusual cutaneous features associated with a heterozygous gain-of-function mutation in IFIH1: overlap between Aicardi-Goutières and Singleton-Merten syndromes.

    Bursztejn AC, Briggs TA, del Toro Duany Y, et al.

    The British journal of dermatology 2015; (173(6)):1505-13 doi:10.1111/bjd.14073.

    PMID: 26284909
  20. 20

    Severe diarrhea in a 10-year-old girl with Aicardi-Goutières syndrome due to IFIH1 gene mutation.

    Lu M, Zhu K, Zheng Q, et al.

    American journal of medical genetics. Part A 2021; (185(10)):3146-3152 doi:10.1002/ajmg.a.62397.

    PMID: 34189822
  21. 21

    An overview of genetic mutations in Aicardi-Goutières syndrome in Iranian population.

    Khalilian S, Fathi M, Miryounesi M, Ghafouri-Fard S

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025; (46(2)):999-1007 doi:10.1007/s10072-024-07824-x.

    PMID: 39470906
  22. 22

    Endocrinopathies in Aicardi Goutières syndrome-A descriptive case series.

    Worth C, Briggs TA, Padidela R, et al.

    Clinical case reports 2020; (8(11)):2181-2185 doi:10.1002/ccr3.3081.

    PMID: 33235754
  23. 23

    Collapsing Glomerulopathy as a Complication of Type I Interferon-Mediated Glomerulopathy in a Patient With RNASEH2B-Related Aicardi-Goutières Syndrome.

    Fenaroli P, Rossi GM, Angelotti ML, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2021; (78(5)):750-754 doi:10.1053/j.ajkd.2021.02.330.

    PMID: 33872687

This page explains the genetics and biology of Aicardi-Goutières syndrome for educational purposes. Always consult a genetic counselor or pediatric neurologist to interpret your child's specific genetic test results.

Stay up to date

Get notified when new research about Aicardi-Goutières syndrome is published.

No spam. Unsubscribe anytime.